BBIO vs CM: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CM is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BBIO and CM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BBIO and CM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

BridgeBio Pharma (NASDAQ: BBIO) is a Palo Alto-based biopharmaceutical company focused on genetic diseases and genetically driven cancers. Its commercial engine is Attruby (acoramidis), an oral TTR stabilizer approved by the FDA in November 2024 for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive and often underdiagnosed heart condition. Attruby competes in a market long dominated by Pfizer's tafamidis franchise, and BridgeBio has been rapidly building prescriber and patient uptake since launch.

Full BBIO guide

Canadian Imperial Bank of Commerce, founded in 1867 and run out of CIBC Square in Toronto, banks roughly 15 million personal, business, public-sector and institutional clients. Reporting today splits into Canadian Personal and Business Banking, Canadian Commercial Banking and Wealth Management, U.S. Commercial Banking and Wealth Management, Capital Markets and Direct Financial Services, plus a Corporate and Other bucket. The balance sheet held ~C$832.8 billion of deposits and ~C$358.4 billion of risk-weighted assets at April 30, 2026, alongside ~C$4.15 trillion of assets under administration and ~C$455 billion under management. Harry Culham became president and chief executive in 2025, and in May 2026 the bank reshuffled its leadership and agreed to sell its 91.67% stake in CIBC Caribbean to Bermuda's Bank of N.T. Butterfield for ~US$1.645 billion, taking US$1 billion in cash and a ~22% equity stake in the buyer. One quirk to keep straight: the fiscal year ends October 31, so quarters are reported on a December, February, May and August cycle.

Full CM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BBIO drivers: Attruby (acoramidis) commercial ramp; Pipeline diversification and 2026 filings.
• CM drivers: Margin expansion in the Canadian retail bank; Redeploying capital into the US franchise.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is concentration: Attruby is BridgeBio's only approved commercial product, so near-term performance is highly dependent on a single therapy in a competitive market. For CM, cIBC carries the heaviest relative exposure to Canadian residential mortgages of the country's large banks, and gross impaired loans reached ~C$3,967 million at April 30, 2026, up ~C$672 million from a year earlier, with the loan loss ratio at 0.38%.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BBIO if you believe its drivers more; CM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BBIO and CM guides.

BBIO. BBIO trades at a rich multiple of trailing revenue, reflecting expectations for continued Attruby growth and pipeline launches rather than current profits. Revenue is expanding rapidly, but the company still posts large net losses as it invests in commercialization and R&D. A $500 million buyback authorized in May 2026 and a cash position near $940 million give it near-term financial flexibility.

CM. Every figure CIBC reports is in Canadian dollars, so screeners that print a CAD revenue line next to a USD market cap will look wrong by roughly 39%. Trailing revenue and EPS above are the sum of the four filed quarters through April 30, 2026, which includes a one-time ~C$422 million tax recovery in the January quarter worth ~C$0.45 of reported EPS. Banks are better judged on net interest margin, return on equity, CET1 and provisions than on a revenue multiple, and the next print, third-quarter fiscal 2026, is scheduled for August 27, 2026.

Headline figures (approximate, Q1 2026): BBIO shows revenue (q1 2026) ~$195M, attruby net revenue (q1 2026) ~$181M, revenue (ttm) ~$500M-$580M, net income (ttm) ~-$733M; CM shows revenue (ttm to apr 30, 2026) ~C$31.2B (~US$22.5B at ~0.72 USD per CAD), latest quarter (q2 fy2026, ended apr 30, 2026) Revenue ~C$8,006M, +14% YoY; net income ~C$2,465M, +23%, diluted eps (ttm) ~C$10.09 reported; adjusted Q2 EPS ~C$2.54, profitability and capital ROE 16.4%, CET1 13.6%, NIM 1.67%, efficiency ratio 52.4%, PCL ~C$605M.

BBIO and CM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BBIO and CM exposure against your real portfolio. It is not an investment adviser.